Document Detail

Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria. A controlled field study.
MedLine Citation:
PMID:  20648774     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The clinical efficacy of Monophosphoryl lipid A-adjuvanted immunotherapy (MPLA-SCIT) is ascertained, but there are no data on its possible long-lasting effect. We assessed in a real-life setting the persistence of the clinical effect five years after discontinuation. METHODS: Patients with parietaria-induced respiratory allergy and fulfilling the criteria for immunotherapy prescription were evaluated at baseline, after the third year of MPLA-SCIT and five years after discontinuation. Visual analog scores, severity of the disease, pulmonary function and skin reactivity were assessed. Matched subjects who refused immunotherapy served as controls. RESULTS: Twenty nine patients received MPLA-SCIT and 28 were the control group. There was a significant clinical improvement, as assessed by VAS only in the active group after 3 years that remained significant at 5 years versus baseline and controls. The distribution of severity of rhinitis was overall decreased at 3 and 8years as well. The number of patients with conjunctivitis in the active group decreased from 19 to 6 at the end of the treatment and to 9 after 5 years. There was also a decrease in the number of patients with asthma symptoms (from 6 to 2 to 4), which doubled in the control group. A significant reduction in the wheal of the Parietaria skin test was seen in the active group at the end of the treatment (9.5 +/- 2.1 mm vs. 6.4 +/- 2.6 mm; p = .01), but this reduction was lost at the 5-year. No relevant change was overall detected in pulmonary function. CONCLUSION: MPLA-SCIT is effective, and the clinical efficacy is maintained after 5 years of discontinuation.
A Musarra; D Bignardi; C Troise; G Passalacqua
Related Documents :
17135734 - Incontinence induces stratum corneum vulnerability and impairs the skin barrier functio...
17034374 - Treatment of osmidrosis with the cavitron ultrasonic surgical aspirator.
12850804 - Photorejuvenation of the forearms by treating hyperpigmented lesions with intense pulse...
21623994 - Elevated preconception cd56(+) 16(+) and/or th1:th2 levels predict benefit from ivig th...
12935844 - Effects of increased ambient temperature on the development of in vitro derived bovine ...
8390014 - Cyclosporin a: early or delayed onset by prophylactic immunosuppression?
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European annals of allergy and clinical immunology     Volume:  42     ISSN:  1764-1489     ISO Abbreviation:  Eur Ann Allergy Clin Immunol     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-07-22     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101466614     Medline TA:  Eur Ann Allergy Clin Immunol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  115-9     Citation Subset:  IM    
Allergy Unit, National Healthcare System, Reggio Calabria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / administration & dosage*
Asthma / therapy
Conjunctivitis / therapy
Desensitization, Immunologic*
Hypersensitivity / therapy*
Injections, Subcutaneous
Lipid A / administration & dosage,  analogs & derivatives*
Parietaria / immunology*
Prospective Studies
Rhinitis / therapy
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Lipid A; 0/monophosphoryl lipid A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The biological potency of different extracts for sublingual immunotherapy assessed by skin prick tes...
Next Document:  The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild ...